SAN DIEGO, CA / ACCESSWIRE / January 27, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Domo, Inc. (NASDAQ:DOMO) shares.

Investors, who purchased shares of Domo, Inc. (NASDAQ:DOMO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On October 17, 2019, a lawsuit was filed against Domo, Inc. over alleged securities laws violations. The plaintiff alleges that the Offering Documents which were filed in connection with the company's initial public stock offering (the "IPO) and that the Defendants made false and/or misleading statements and/or failed to disclose that Domo was experiencing weakness in its enterprise and international businesses, that Domo's billings growth had dramatically slowed, that all of the foregoing was reasonably likely to have a material negative impact on the Company's financial results, and that as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein and the Company's public statements were materially false and misleading at all relevant times.

Those who purchased Domo, Inc. (NASDAQ:DOMO) shares should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 574159

SAN DIEGO, CA / ACCESSWIRE / January 27, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Merit Quad/Graphics, Inc. (NYSE:QUAD) shares.

Investors, who purchased shares of Quad/Graphics, Inc. (NYSE:QUAD) in 2018 or earlier and continue to hold any of their NYSE: QUAD shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The plaintiff alleges that the defendants failed to disclose to investors that the Company's book business in United States was underperforming, that, as a result, the Company was likely to divest its book business, that the Company was unreasonably vulnerable to decreases in market prices, that, to remain financially flexible while market prices decreased, the Company was likely to cut its quarterly dividend and expand its cost reduction programs, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Those who purchased Quad/Graphics, Inc. (NYSE:QUAD) shares should contact the Shareholders Foundation, Inc.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 574158

VANCOUVER, BRITISH COLUMBIA / ACCESSWIRE / January 27, 2020 / ELSE NUTRITION HOLDINGS INC. (TSX-V:BABY)(OTCQB:BABYF) ("Else Nutrition", "Else" or the "Company"), a developer of a real alternative to dairy-based infant nutrition, is pleased to announce the following updates to shareholders.

Key Highlights

A U.S. Market Research Study of 1,858 statistically significant potential customers shows very favorable results
82% of respondents indicating a favorable view of the Else product concept
Over 60% Purchase Intent of Else baby formula products.

Else Nutrition concluded a comprehensive U.S. customer study, conducted by Wizer, a leading market research provider. The study assessed the perceptions, needs and behavior of parents/caregivers regarding their children's nutrition, and their response to Else Nutrition product concept. The web-based survey of over 1,858 prospective customers (who are the primary decision makers regarding household grocery purchases) spanned 13 major U.S. metropolitan areas, including NYC, Los Angeles, Chicago, Boston, Washington D.C., Philadelphia, Miami, San Francisco, San Diego, Seattle, and Portland OR. All surveyed have a child between the ages of 3 months to 3 years of age.

The key findings showed that:

Over 82% (Top 2 boxes) of respondents react favorably to the Else brand concept.
Over 60% (Top 2 boxes) of respondents indicated positive Purchase Intent for Else's baby formula products.

Both metrics show significant favorability compared to benchmarks for consumer goods products.

Additionally, the study confirmed that 40% of current U.S. infant nutrition consumers buy a specialty formulation (i.e. medical/prescribed milk formula, soy-based formula, or sensitive milk formula) for their children. Else Nutrition's baby formula is the only non-dairy non-soy veritable alternative for this massive, US$2 billion U.S. specialty formula market.1

"These findings are very encouraging as we introduce our product to the U.S. market this year. Additionally, these data points truly signal a shift in the market toward healthy, plant-based, clean label products for babies and children," stated Ms. Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition.

"It's clear that there's a real need for an alternative. We've now validated and have resounding, statistical confirmation from American parents and caregivers that they want these products now. Specifically, we have learned that a nutritious, plant-based and healthy alternative can fill a real gap in the current market, and touch the lives of modern families," she added.

1 Euromonitor International, September 2018, Baby Food in the US

About Else Nutrition Holdings Inc.

Else Nutrition is a mission-driven company focused on revolutionizing infant and toddler nutrition through its 100% plant-based and non-soy alternative to dairy-based baby formula. Winner of the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan, Else's innovative toddler formula will be launching in the United States in 2020. For more information, visit: elsenutrition.com.

About Wizer

Wizer provides the technology framework for consumer-centric organizations. The company integrates consumer intelligence into both tactical and strategic product and marketing decision-making at scale. Wizer's unique technology is easily tailored. The company provides a complete solution for preparing, analyzing and visualizing consumer data. For more information about Wizer, visit: getwizer.com.

For more information, contact:

Ms. Chelsie Hodge, Director of Corporate Relations
ELSE Nutrition Holdings Inc.
E: chelsieh@elsenutrition.com
P: (604)360-2977

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: hamutaly@elsenutrition.com
P: +972(0)52-447-9931

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that, to the extent they are not recitations of historical fact, constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will", "plan", "hope to", "intend" or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements with respect to: the Company's commercialization of its products and expected timing, expected go-to-market strategy (including marketing, proposed markets, sales, customer growth and market position), and industry conditions.

Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct.

Forward-looking statements made in this press release assume, among others, the successful completion of Else's proposed scale-up for its products, and such statements are intended to apply only to the infant formula market for ages 12 months and above, and having all necessary regulatory approval as required by each target market.

Numerous risks and uncertainties could cause the Company's actual results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to: consumer demand for the Company's products, whether the Company's current and future products achieve commercialization, uncertainty regarding material changes in laws and regulations, retention of key personnel, the Company's ability to expand into global markets and competitive developments.

The foregoing list of factors is not exhaustive, and other risks and uncertainties not presently known, or believed to be material, to management Additional information and other factors that could affect the operations or financial results of the Company are set out in the Company's Filing Statement dated May 14, 2019 under the heading "Risk Factors" and may be accessed through the SEDAR website (www.sedar.com).

Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: ELSE Nutrition Holdings

ReleaseID: 574140

TORONTO, ON / ACCESSWIRE / January 27, 2020 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has been granted a U.S. Patent for Multiwavelength PhotoDynamic Therapy ("PDT") technology.

The U.S. patent entitled "Apparatus and Method for Multiwavelength Photodynamic Therapy" allows Theralase to use various laser wavelengths in the activation of PhotoDynamic Compounds ("PDC") in cancerous tumours. The advantage is that a large or deep seated tumour may be only partially destroyed with laser of a particular wavelength, but then fully destroyed by employing one or two additional laser wavelengths, as different laser wavelengths are able to penetrate to different tissue depths. This would be especially important for cancers, such as Glio Blastoma Multiforme ("GBM") or Non-Small Cell Lung Cancer ("NSCLC").

Dr. Arkady Mandel M.D., Ph.D., D.Sc, Chief Scientific Officer of Theralase stated, "Theralase specializes in the development of safe, effective and targeted cancer therapy. This U.S. patent increases Company value by protecting optimized PDT technology which would be effective in large or difficult to reach tumours that are not accessible by certain laser wavelengths. Theralase continues to develop a comprehensive intellectual property portfolio, which strengthens Theralase's position in the global oncology market."

The global market for oncology therapeutic medicines will reach as high as $200 billion by 2022, with the U.S. market reaching as high as $100 billion by 2022, averaging 12-15% growth1.

About Theralase® Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.

Additional information is available at www.theralase.com and www.sedar.com

1 Coherent Market Insights. https://www.marketwatch.com/press-release/global-oncology-drugs-market-to-surpass-us-1962-billion-by-2026-2019-01-30

This news release contains "forward-looking statements" which reflect the current expectations of the Company's management of future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273)
416.699.LASE (5273)

Shushu Feng, Investor Relations & Public Relations Coordinator
sfeng@theralase.com

Amelia Tudo, Investor Relations & Public Relations Coordinator
atudo@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 574078

VANCOUVER, BC / ACCESSWIRE / January 27, 2020 / Scorpio Gold Corporation ("Scorpio Gold" or the "Company") (TSXV:SGN) is pleased to announce the signing of a Toll Milling Agreement (the "Agreement") between the Company's affiliate, Goldwedge LLC, and Lode-Star Mining Inc. ("Lode-Star"). The Agreement will allow for the processing of ore delivered from Lode-Star's mining properties to Scorpio Gold's 400 ton per day Goldwedge milling facility located in Manhattan, Nevada.

Under the terms of the Agreement, Lode-Star will advance funds required for the design engineering, permitting and mill modifications required for processing of Lode-Star's ore. Based on previous metallurgical testing, Lode-Star's ore requires gravity combined with flotation for optimal recoveries of contained precious metals. The Goldwedge milling circuit is currently configured with a gravity recovery circuit. The modifications to the Goldwedge milling facility will include the addition of a flotation circuit, supporting reagent tanks/silos, secondary lining of process containment ponds, leak detection and monitoring wells associated with fluid containments. The Agreement provides for Lode-Star to recoup the advanced funds through a reduction in toll milling rates until all advanced funds have been repaid. Following repayment, the toll charges will revert to standard rates.

This Agreement is mutually beneficial for both parties. Goldwedge LLC will transition from temporary closure into production. With the addition of a flotation circuit the Goldwedge milling facility will have the capability of processing carbonaceous/sulfidic ores, expanding its availability for toll milling in addition to the Lode-Star arrangement. The new flotation circuit will also result in improved recoveries for mineralized material within the Goldwedge deposit, potentially allowing for lower mining cut-off grades. Lode-Star benefits from having a long-term processing agreement for their ores at a location operated by an experienced processing team. The mill is in close proximity to their mine, thus minimizing haulage costs, and will have a milling circuit optimized for peak metallurgical recoveries.

Scorpio Gold's President, Chris Zerga, comments, "This toll milling agreement is the achievement of many hours of work between Lode-Star and Scorpio Gold's management and both parties will greatly benefit from it. We look forward to working with the Lode-Star team and positioning the Goldwedge mill for additional toll-milling opportunities."

About Scorpio Gold

Scorpio Gold holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada with a fully permitted underground mine and 400 ton per day mill facility. Scorpio Gold also holds a 100% interest in the Mineral Ridge gold mining operation located in Esmeralda County, Nevada. Mineral Ridge is a conventional open pit mining and heap leach operation. Mining at Mineral Ridge was suspended in November 2017; however, the Company continues to generate limited revenues from residual but diminishing recoveries from the leach pads.

Scorpio Gold's Chairman, Peter J. Hawley, P.Geo., is a Qualified Person as defined in National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Brian Lock
Interim CEO

For further information contact:

Brian Lock
Tel: (604) 889-2543
Email: block@scorpiogold.com

Chris Zerga, President
Tel: (604) 536-2711
Email: czerga@scorpiogold.com

Website: www.scorpiogold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The Company relies on litigation protection for forward-looking statements. This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "suggest", "indicate" and other similar words or statements that certain events or conditions "may" or "will" occur, and include, without limitation, statements regarding the Company's plans with respect to toll milling at its Goldwedge milling facility. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks involved in mill modifications, toll milling operations and those risk factors outlined in the Company's Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.

SOURCE: Scorpio Gold Corporation

ReleaseID: 574104

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

DIDCOT, UK / ACCESSWIRE / January 27, 2020 / Altus Strategies Plc (AIM:ALS)(TSX-V:ALTS), the Africa focused project and royalty generator, announces that it has closed the second and final tranche ("Second Tranche") of its non-brokered private placement ("Placement"), as previously announced on 20 December 2019. The Second Tranche comprised 14,000,000 new Ordinary Shares ("Ordinary Shares") from a total offering of 46,328,802 Ordinary Shares at an issue price of C$0.09 / £0.052 per share. The gross proceeds of the Placement were C$4,169,592 / £2,409,098 (before expenses), with the Second Tranche representing C$1,260,000 / £728,000 (before expenses).

Steve Poulton, Chief Executive of Altus, commented:

"We are delighted to close the Second Tranche of the Placement. Since we announced the Placement, Altus has called a general meeting of its shareholders on 18 February 2020 to approve the strategic investment in Altus by La Mancha of C$11.2 million / £6.5 million at C$0.09 per share. Taking the Placement and the La Mancha investment together, Altus is positioned for a transformative 2020. We are looking forward to accelerating our project and royalty generation activities, as well as securing further value accretive opportunities."

Details of the Second Tranche

The Second Tranche of 14,000,000 Ordinary Shares were issued to Delphi Unternehmensberatung Aktiengesellschaft ("Delphi") of Heidelberg Germany and amount to C$1,260,000 / £728,000 (before expenses). Altus understands that Delphi now owns 35,000,000 Ordinary Shares, representing approximately 15.47% of the issued share capital of the Company.

Details of the Placement

The Placement is conditional on the admission of the new Ordinary Shares to trading on the AIM market ("AIM") of the London Stock Exchange. Application has been made for 14,000,000 new Ordinary Shares to begin trading on AIM and it is expected that admission and dealings in the new Ordinary Shares will commence on AIM at 8.00 a.m. on, or around, 29 January 2020. No finder fees or other commissions were paid in respect of the Placement. The Placement comprises 46,328,802 Ordinary Shares which, including the Second Tranche, represents approximately 20.48% of the Company's issued share capital.

Total Voting Rights

Following the Second Tranche, there are a total of 226,228,461 issued Ordinary Shares, none of which are held in treasury. Shareholders should use that number as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

No offer or solicitation

This Announcement is for information purposes only and does not constitute an invitation to any person to purchase or subscribe for Ordinary Shares or any other securities or engage in any form of investment activity. This Announcement is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States of America its territories and possessions, any state of the United States or the District of Columbia (collectively, the "United States"), Australia, Japan, New Zealand or the Republic of South Africa or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction. This Announcement is also being released in Canada as part of the Company' continuous disclosure record.

This Announcement is directed only at persons in member states of the European Economic Area ("EEA") who are qualified investors within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended from time to time (the "Prospectus Regulation"), ("Qualified Investors"). In addition, in the United Kingdom, this Announcement and any offer if made subsequently is directed only at Qualified Investors, who are also (i) persons who have professional experience in matters relating to investments falling within the definition of "Investment Professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) high net worth entities falling within Article 49(2) of the Order or (iii) other persons to whom it may lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This Announcement must not be acted on or relied on (i) in any member state of the European Economic Area, by any person who is not a Qualified Investor (ii) in the UK, by any person who is not a Relevant Person.

For further information you are invited to visit the Company's website www.altus-strategies.com or contact:

Altus Strategies Plc

Steven Poulton, Chief Executive

Tel: +44 (0) 1235 511 767

E: info@altus-strategies.com

SP Angel (Nominated Adviser)

Richard Morrison / Soltan Tagiev

Tel: +44 (0) 20 3470 0470

SP Angel (Broker)

Abigail Wayne / Richard Parlons

Tel: +44 (0) 20 3470 0471

Blytheweigh (Financial PR)

Tim Blythe / Camilla Horsfall

Tel: +44 (0) 20 7138 3204

About Altus Strategies Plc

Altus is a London (AIM: ALS) and Toronto (TSX-V: ALTS) listed project and royalty generator in the mining sector with a focus on Africa. Our team creates value by making mineral discoveries across multiple licences. We enter joint ventures with respected groups and our partners earn interest in these discoveries by advancing them toward production. Project milestone payments we receive are reinvested to extend our portfolio, accelerating our growth. The portfolio model reduces risk as our interests are diversified by commodity and by country. The royalties generated from our portfolio of projects are designed to yield sustainable long-term income. We engage constructively with all our stakeholders, working diligently to minimise our environmental impact and to promote positive economic and social outcomes in the communities where we operate.

Cautionary Note Regarding Forward-Looking Statements

Certain information included in this Announcement, including information relating to future financial or operating performance and other statements that express the expectations of the Directors or estimates of future performance constitute "forward-looking statements". These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include without limitation the completion of planned expenditures, the ability to complete exploration programmes on schedule and the success of exploration programmes. Readers are cautioned not to place undue reliance on the forward-looking information, which speak only as of the date of this Announcement and the forward-looking statements contained in this announcement are expressly qualified in their entirety by this cautionary statement.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. The forward-looking statements contained in this Announcement are made as at the date hereof and the Company assumes no obligation to publicly update or revise any forward-looking information or any forward-looking statements contained in any other announcements whether as a result of new information, future events or otherwise, except as required under applicable law or regulations.

Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Disclaimer

SP Angel Corporate Finance LLP, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and no one else (including the recipients of this announcement) as nominated adviser and will not be responsible to anyone other than the Company for providing the protections afforded to customers of SP Angel Corporate Finance LLP or for advising any other person in relation to the matters described in this announcement.

Market Abuse Regulation Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR") until the release of this announcement. In addition, market soundings (as defined in MAR) were taken in respect of the placing and other matters contained in this announcement, with the result that certain persons became aware of such inside information, as permitted by MAR. That inside information is set out in this announcement and is now considered to be in the public domain. Therefore, upon the publication of this announcement, those persons that received is inside information in a market sounding are no longer in possession of inside information relating to the Company and its securities.

SOURCE: Altus Strategies PLC

ReleaseID: 574131